Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study-Reference-Cited by-同舟云学术

Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study

Published:2024-06-22 Issue:7 Volume:40 Page:1137-1143
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Bir Yücel Kadriye¹^ORCID,Uğraklı Muzaffer²^ORCID,Sekmek Serhat³,Yıldırım Nilgün⁴^ORCID,Gürler Fatih¹^ORCID,Yazıcı Ozan¹^ORCID,Özet Ahmet¹^ORCID,Bal Öznur³^ORCID,Araz Murat²^ORCID,Artaç Mehmet²^ORCID,Özdemir Nuriye¹^ORCID

Affiliation:

1. Department of Medical Oncology, Gazi University, Ankara, Turkey

2. Department of Medical Oncology, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey

3. Department of Medical Oncology, Bilkent City Hospital, Ankara, Turkey

4. Department of Medical Oncology, Fırat University Faculty of Medicine, Elazığ, Turkey

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2366430

Reference23 articles.

1. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

2. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

3. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

4. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

5. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial